Glaucoma drug may have potential to treat Alzheimer's disease

December 9, 2016 by Margaret-Anne Orgill, University College London
Credit: University College London

A drug which is used to treat the common eye disease glaucoma may have potential as a treatment for Alzheimer's disease, according to scientists at UCL.

In trials on rats, the drug brimonidine, which is routinely used to lower eye pressure in glaucoma patients, has been found to reduce the formation of in the retina, which are believed to be linked to Alzheimer's. The research was reported in the journal Cell Death and Disease.

Amyloid plaques can be seen in the retinas of people with Alzheimer's, so the researchers say the retina can be viewed as an extension of the brain that provides an opportunity to diagnose and track progression of Alzheimer's.

Scientists found that brimonidine reduces neurodegeneration of cells in the retina by cutting the levels of beta amyloid in the eye. This was achieved by using the drug to stimulate the production of an alternative non-toxic protein which does not kill .

The researchers hope that the drug will have a similar effect on the brain, although this was not tested in the current study.

"The findings of our study could not have come at a more significant and important moment, given the increased prevalence of Alzheimer's disease.  As we live longer, there will be increasing demand for therapies that can help challenge this extremely damaging and we believe that our findings can make a major contribution," said Professor Francesca Cordeiro (UCL Institute of Ophthalmology) who led the study.

Explore further: 'Pac-Man' gene implicated in Alzheimer's disease

More information: Shereen Nizari et al. Non-amyloidogenic effects of α2 adrenergic agonists: implications for brimonidine-mediated neuroprotection, Cell Death and Disease (2016). DOI: 10.1038/cddis.2016.397

Related Stories

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Experimental drug shows promise in treating Alzheimer's disease

October 25, 2016
An experimental drug shows promise in treating Alzheimer's disease by preventing inflammation and removing abnormal protein clumps in the brain that are associated with the disease, suggests a study in mice presented at the ...

Alzheimer's detected before symptoms via new eye technology

July 11, 2016
Rockville, Md. Scientists may have overcome a major roadblock in the development of Alzheimer's therapies by creating a new technology to observe—in the back of the eye—progression of the disease before the onset of symptoms. ...

Cannabinoids remove plaque-forming Alzheimer's proteins from brain cells

June 29, 2016
Salk Institute scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer's ...

Recommended for you

New discoveries predict ability to forecast dementia from single molecule

December 11, 2018
Scientists who recently identified the molecular start of Alzheimer's disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time—a form of personalized ...

Researchers classify Alzheimer's patients in six subgroups

December 5, 2018
Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments.

Neuroscientists pinpoint genes tied to dementia

December 3, 2018
A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an important step on the path toward developing therapies that could slow or halt the course of the disease. ...

Detecting signs of neurodegeneration earlier and more accurately

November 30, 2018
Signs of neurodegenerative diseases, appearing years before the emergence of clinical manifestations, can be detected during the examination of medical samples by means of fluorescence microscopy by using new sensitive and ...

Never-before-seen DNA recombination in the brain linked to Alzheimer's disease

November 21, 2018
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified gene recombination in neurons that produces thousands of new gene variants within Alzheimer's disease brains. The study, published today ...

New information on the pathological mechanisms of Alzheimer's disease

November 21, 2018
Researchers at the University of Helsinki have discovered a mechanism by which harmful tau protein aggregates are transmitted between neurons. Alongside amyloid plaques, tau aggregates in the brain are a significant factor ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.